All Articles

UBS sees dozens of its Southeast advisors on Barron's 2026 list, signaling a strategic victory in a key growth market. What does this mean for clients?

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

Roche has received FDA clearance for two new high-speed diagnostic units designed to alleviate lab staff shortages and dramatically increase testing capacity.

Beyond apparel, Anthropologie and FARM Rio's new home line is a strategic play on maximalism, sustainability, and the power of a decade-long partnership.

HealthEquity adds Sanford Health CEO Bill Gassen to its board, a strategic move to infuse provider-side expertise into the HSA giant's future.

With a fresh $6M infusion bringing its Series A to $36M, FIZE Medical is accelerating its global push for AI-powered, proactive fluid management in ICUs.

A new pocket-sized, AI-powered ultrasound aims to revolutionize prenatal care in Africa, putting life-saving diagnostics into the hands of local caregivers.

HistoSonics begins a landmark trial for a non-invasive BPH therapy that uses focused ultrasound to mechanically destroy tissue without incisions or heat.

The Christopher Street Project’s massive rally on the National Mall united thousands to demand action and directly engage lawmakers on trans rights.

A new partnership between Takara Bio and Hamilton promises to revolutionize RNA-seq, making high-throughput genomic analysis faster and more reliable.

Arax Investment Partners adds family-run Omni Financial, highlighting a major trend of boutique firms joining PE-backed giants for growth and succession.

Tenpoint Therapeutics launches YUVEZZI, a once-daily drop for presbyopia, entering a fierce market with a novel two-in-one formula for aging eyes.

German CDMO Vetter wins a prestigious, client-voted award, underscoring its pivotal role and massive €2 billion investment in the world of injectable biologics.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new SMART on FHIR app from AmericaWest lets hospital staff book medical rides in Epic, reducing a 31-minute task to less than one minute.

A new partnership aims to merge digital brain therapies with functional foods, targeting Japan and Southeast Asia's rapidly growing elderly populations.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

Dubai's AIR, owner of Al Fakher, is going public via a SPAC merger. Can it navigate a tricky market and health debates to find growth on Wall Street?

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.